A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients With Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia

Trial Profile

A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients With Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 May 2018

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms PACE
  • Sponsors ARIAD Pharmaceuticals
  • Most Recent Events

    • 02 May 2018 Planned End Date changed from 1 May 2017 to 30 Sep 2018.
    • 02 May 2018 Planned primary completion date changed from 1 May 2017 to 30 Sep 2018.
    • 22 Mar 2018 Final 5-year results of the study (data cut off: 6 Feb, 2017) published in the Blood.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top